OptiNose(OPTN) - 2024 Q3 - Quarterly Results

Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights Company reports Q3 2024 XHANCE net revenue of $20.4 million, an increase of 3% compared to Q3 2023 Company reports positive inflection in new prescriptions of XHANCE starting in September Company decreases full year 2024 XHANCE net revenue guidance to be between$ 75.0 to $79.0 million and increases expected average net revenue per prescription guidance to be approximately$ 270 Company decreases full year 2024 operating e ...